Cargando…
Engineering precision nanoparticles for drug delivery
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717100/ https://www.ncbi.nlm.nih.gov/pubmed/33277608 http://dx.doi.org/10.1038/s41573-020-0090-8 |
_version_ | 1783619288997822464 |
---|---|
author | Mitchell, Michael J. Billingsley, Margaret M. Haley, Rebecca M. Wechsler, Marissa E. Peppas, Nicholas A. Langer, Robert |
author_facet | Mitchell, Michael J. Billingsley, Margaret M. Haley, Rebecca M. Wechsler, Marissa E. Peppas, Nicholas A. Langer, Robert |
author_sort | Mitchell, Michael J. |
collection | PubMed |
description | In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. |
format | Online Article Text |
id | pubmed-7717100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77171002020-12-07 Engineering precision nanoparticles for drug delivery Mitchell, Michael J. Billingsley, Margaret M. Haley, Rebecca M. Wechsler, Marissa E. Peppas, Nicholas A. Langer, Robert Nat Rev Drug Discov Review Article In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. Nature Publishing Group UK 2020-12-04 2021 /pmc/articles/PMC7717100/ /pubmed/33277608 http://dx.doi.org/10.1038/s41573-020-0090-8 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Mitchell, Michael J. Billingsley, Margaret M. Haley, Rebecca M. Wechsler, Marissa E. Peppas, Nicholas A. Langer, Robert Engineering precision nanoparticles for drug delivery |
title | Engineering precision nanoparticles for drug delivery |
title_full | Engineering precision nanoparticles for drug delivery |
title_fullStr | Engineering precision nanoparticles for drug delivery |
title_full_unstemmed | Engineering precision nanoparticles for drug delivery |
title_short | Engineering precision nanoparticles for drug delivery |
title_sort | engineering precision nanoparticles for drug delivery |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717100/ https://www.ncbi.nlm.nih.gov/pubmed/33277608 http://dx.doi.org/10.1038/s41573-020-0090-8 |
work_keys_str_mv | AT mitchellmichaelj engineeringprecisionnanoparticlesfordrugdelivery AT billingsleymargaretm engineeringprecisionnanoparticlesfordrugdelivery AT haleyrebeccam engineeringprecisionnanoparticlesfordrugdelivery AT wechslermarissae engineeringprecisionnanoparticlesfordrugdelivery AT peppasnicholasa engineeringprecisionnanoparticlesfordrugdelivery AT langerrobert engineeringprecisionnanoparticlesfordrugdelivery |